Market›Gataparsen
Company Profile

Gataparsen

Gataparsen is an antisense oligonucleotide that complementarily binds to survivin mRNA and inhibits its expression in tumor tissue.

Clinical trials
It has completed a phase II trial for acute myeloid leukemia. A phase II trial for non-small cell lung cancer has started. A phase II trial for hormone-refractory prostate cancer will run until early 2012. == References ==
Source: Wikipedia ↗
tickerdossier.comtickerdossier.substack.com